Evidence map›Paper›PMID 40998834›Full record

ArticleNPJ Parkinson's disease2025

Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson's disease patients.

Jacopo Gervasoni, Carmen Marino, Alberto Imarisio, Lavinia Santucci, Enza Napolitano, Tommaso Nuzzo, Isar Yahyavi, Micol Avenali, Michela Cicchinelli, Gabriele Buongarzone and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Frailty in Parkinson's disease: time to integrate it into treatment decision-making?Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jacopo Gervasoni *Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Carmen Marino *Department of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.
Alberto Imarisio *Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Lavinia SantucciFondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Enza NapolitanoDepartment of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.
Tommaso NuzzoDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy.
Isar YahyaviDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy.
Micol AvenaliDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Michela CicchinelliUniversità Cattolica del Sacro Cuore, Roma, Italy.
Gabriele BuongarzoneDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Caterina GalandraNeurogenetics Research Centre, IRCCS Mondino Foundation, Pavia, Italy.
Marta PicasciaParkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Pavia, Italy.
Manuela GrimaldiDepartment of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.
Claudio PacchettiParkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Pavia, Italy.
Francesco ErricoCEINGE Biotecnologie Avanzate Franco Salvatore, Naples, Italy.
Anna Maria D'UrsiDepartment of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.
Andrea UrbaniFondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. andrea.urbani@unicatt.it.
Enza Maria ValenteDepartment of Molecular Medicine, University of Pavia, Pavia, Italy. enzamaria.valente@unipv.it.
Alessandro UsielloDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy. alessandro.usiello@unicampania.it.

Funding

Fondazione Cariplo 2017-0575Ministero della Salute Ricerca Corrente 2022-2024Ministero dell'Università e della Ricerca MNESYS (PE0000006)
6 · The paper itself

Abstract

Whether distinct blood metabolomic profiles can distinguish Parkinson's disease (PD) patients from healthy controls (HC) is still a matter of debate. Here, we employed ¹H-NMR and UPLC/MS analyses on serum samples from a cohort of PD patients and HC. Compared to HC, PD patients showed: (1) higher glutamine, serine, pyruvate and lower α-ketoglutarate levels (

Identifiers

PMID40998834
PMCPMC12462461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.